Evista (raloxifene) is now approved to TREAT osteoporosis

Evista (raloxifene) is now approved to TREAT osteoporosis...it used to be approved only for prevention.

Evista decreases vertebral fractures up to 50%...in postmenopausal women who take it for 3 years.

This is comparable to the decrease in vertebral fractures that's seen with Fosamax (alendronate)...even though Evista doesn't increase bone density as much as Fosamax.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote